Cumulative Clinical Trial Experience with Levofloxacin for Patients with Community-Acquired Pneumonia-Associated Pneumococcal Bacteremia

Cumulative Clinical Trial Experience with Levofloxacin for Patients with Community-Acquired Pneumonia-Associated Pneumococcal Bacteremia

Streptococcus pneumoniae has been isolated in up to two-thirds of all cases of community-acquired pneumonia (CAP), and pneumococcal bacteremia has been associated in 20%–25% of these cases. The recent literature has suggested that better outcomes are achieved with the use of combination therapy for...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases Vol. 38; no. Supplement-1; pp. S34 - S42
Main Authors: Kahn, J. B., Bahalr, N., Wiesinger, B. A., Xiang, J.
Format: Journal Article
Language:English
Published: The University of Chicago Press 15-01-2004
University of Chicago Press
Subjects:
Antimicrobials
Bacteremia
Dosage
Fluoroquinolones
Health outcomes
Macrolides
Mortality
Pneumococcal pneumonia
Pneumonia
Streptococcus pneumoniae
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Streptococcus pneumoniae has been isolated in up to two-thirds of all cases of community-acquired pneumonia (CAP), and pneumococcal bacteremia has been associated in 20%–25% of these cases. The recent literature has suggested that better outcomes are achieved with the use of combination therapy for the treatment of pneumococcal bacteremia. The present study analyzed the efficacy of levofloxacin monotherapy in the treatment of patients with a diagnosis of pneumococcal bacteremia who participated in clinical trials for the treatment of CAP. A total of 108 patients from 9 clinical trials were identified as having pneumococcal bacteremia, including 12 patients infected with penicillin- ormacrolide-resistant strains. Overall, 98 (90.7%) of 108 microbiologically evaluable patients had a successful clinical response, including 11 (91.7%) of 12 patients infected with a macrolide- or penicillin-resistant strain. The mortality rate in this population was <1%. The present study suggests that levofloxacin monotherapy can be an effective choice for the treatment of CAP-associated pneumococcal bacteremia.
Bibliography:ark:/67375/HXZ-95QF84TJ-0
istex:AC0F308500E9386077B255054291C20AB3E6D8B2
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1058-4838
1537-6591
DOI:10.1086/378408